来那度胺联合剂量调整EPOCH-R治疗MYC相关弥漫大B细胞淋巴瘤的多中心1/2期试验
这项研究者发起的多中心1/2期研究评估来那度胺联合DA-EPOCH-R治疗初诊双打击淋巴瘤和双表达淋巴瘤成人患者,共入组55例(DHL 23例,DEL 32例)。总缓解率90.9%,完全缓解率83.6%,中位随访3.4年,1年和2年无进展生存率分别为85.5%和78.2%,达到主要疗效终点。
要点
- 来那度胺联合DA-EPOCH-R在初诊DHL和DEL中总缓解率90.9%,完全缓解率83.6%。
- 中位随访3.4年,1年和2年无进展生存率分别为85.5%和78.2%,2年总生存率83.6%。
- 最常见≥3级不良事件为中性粒细胞减少67%、贫血67%、血小板减少49%、中性粒细胞减少性发热35%。
核心结论
- 来那度胺联合DA-EPOCH-R治疗DEL和DHL患者缓解率高、生存结果令人鼓舞,并达到主要无进展生存疗效标准。
- 作者认为需要开展DA-EPOCH-R联合或不联合来那度胺的随机试验以确定来那度胺的具体获益。
研究设计与样本
- 研究者发起的多中心1/2期研究,评估来那度胺联合DA-EPOCH-R治疗初诊DHL和DEL成人患者。
- 共入组并治疗55例患者,其中DHL 23例,DEL 32例。
- 患者中位年龄65岁(范围25-82),国际预后指数≥3者占69%(38/55),III/IV期占91%(50/55)。
- 试验在ClinicalTrials.gov注册,注册号为NCT02213913。
主要发现
- 总缓解率为90.9%,完全缓解率为83.6%。
- 中位随访3.4年,1年和2年无进展生存率分别为85.5%和78.2%,达到主要终点疗效标准。
- 2年总生存率为83.6%。
- 最常见≥3级不良事件为中性粒细胞减少(67%)、贫血(67%)、血小板减少(49%)和中性粒细胞减少性发热(35%)。
- 无5级事件;6例患者(11%)发生第二原发恶性肿瘤。
关键数值与推荐
- 主要终点疗效标准达到:1年无进展生存率85.5%,2年无进展生存率78.2%。
- 总缓解率90.9%,完全缓解率83.6%,2年总生存率83.6%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者认为需要开展DA-EPOCH-R联合或不联合来那度胺的随机试验以确定来那度胺的具体获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In patients with diffuse large B-cell lymphoma (DLBCL), concurrent deregulation of MYC and BCL2 confers inferior outcomes following R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). DA-EPOCH-R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) produces favorable results in patients with dual MYC and BCL2 rearrangement (double-hit lymphoma [DHL]), but there are limited prospective data in both DHL and DLBCL with dual protein overexpression of Myc and Bcl2 (double-expressor lymphoma [DEL]). Lenalidomide (LEN) may enhance the response in MYC-driven lymphomas, prompting this investigator-initiated multicenter phase 1/2 study evaluating LEN with DA-EPOCH-R in adults with newly diagnosed DHL and DEL. Fifty-five patients (DHL, 23; DEL, 32) were enrolled and treated. Patients had a median age of 65 years (range, 25-82), International Prognostic Index ≥3 in 69% (38/55), and stage III/IV in 91% (50/55). The overall response rate was 90.9%, with a complete response rate of 83.6%. With a median follow-up of 3.4 years, the primary end point efficacy criterion was met with 1- and 2-year progression-free survival (PFS) rates of 85.5% and 78.2%, respectively. The 2-year overall survival was 83.6%. The most common adverse events (grade ≥3) were neutropenia (67%), anemia (67%), thrombocytopenia (49%), and neutropenic fever (35%). There were no grade 5 events. Second primary malignancy occurred in 6 patients (11%). LEN with DA-EPOCH-R for patients with DEL and DHL has a high response rate, encouraging survival, and met the primary PFS efficacy criterion. A randomized trial of DA-EPOCH-R with and without LEN would be needed to determine the specific benefit of LEN. This trial was registered at www.ClinicalTrials.gov as #NCT02213913.
引用
- Cahill K, Godfrey J, Nabhan C, et al. A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL. Blood Adv. 2025. PMID: 40720747. doi:10.1182/bloodadvances.2025017092
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。